"Hanzl\u00EDkov\u00E1, Jitka" . "myelodysplastic syndrome; 5q deletion; fluorescence in situ hybridization (M-FISH)"@en . . "Krop\u00E1\u010Dkov\u00E1, Jitka" . "2"^^ . . . . "5" . "Jaro\u0161ov\u00E1, Marie" . "Vnit\u0159n\u00ED l\u00E9ka\u0159stv\u00ED" . "Cytogenetics and molecular cytogenetics of myelodysplastic syndrom (MDS)"@en . . . . . . "9"^^ . "Myelodysplastick\u00FD syndrom je klon\u00E1ln\u00ED hematopoetick\u00E9 onemocn\u011Bn\u00ED charakterizovan\u00E9 cytopeni\u00ED a dysplasi\u00ED kostn\u00ED d\u0159en\u011B. Je to onemocn\u011Bn\u00ED vy\u0161\u0161\u00EDho v\u011Bku s medi\u00E1nem 60 let. Pro MDS je charakteristick\u00E1 \u0161patn\u00E1 odpov\u011B\u010F na chemoterapii s dlouhodob\u00FDmi cytopeniemi a n\u00EDzk\u00FDm po\u010Dtem remis\u00ED. U 25-30 % nemocn\u00FDch doch\u00E1z\u00ED po ur\u010Dit\u00E9 dob\u011B k postupn\u00E9mu v\u00FDvoji MDS do akutn\u00ED leukemie, nej\u010Dast\u011Bji do akutn\u00ED myeloidn\u00ED leukemie. U d\u011Bt\u00ED se MDS vyskytuje jen z\u0159\u00EDdka a pokud se vyskytne, je charakterizov\u00E1no rychlej\u0161\u00EDm pr\u016Fb\u011Bhem a zvratem do akutn\u00ED leukemie. Cytogenetick\u00E9 zm\u011Bny hraj\u00ED d\u016Fle\u017Eitou roli v patogenesi, diagnose a prognose a v posledn\u00ED dob\u011B se zvy\u0161uje i jejich v\u00FDznam p\u0159i v\u00FDb\u011Bru c\u00EDlen\u00E9 l\u00E9\u010Dby nemocn\u00FDch s MDS. Zm\u011Bny chromosom\u016F se objevuj\u00ED v erytroidn\u00EDch, myeloidn\u00EDch a megakaryocyt\u00E1rn\u00EDch prekursorov\u00FDch bu\u0148k\u00E1ch, co\u017E sv\u011Bd\u010D\u00ED o vzniku neoplasie v pluripotentn\u00ED kmenov\u00E9 bu\u0148ce. Chromosomov\u00E9 zm\u011Bny jsou p\u0159\u00EDtomn\u00E9 asi u 50 % nemocn\u00FDch s de novo MDS a a\u017E v 80 % nemocn\u00FDch se sekund\u00E1rn\u00ED MDS. Balancovan\u00E9 chromosomov\u00E9 zm\u011Bny, kter\u00E9 zahrnuj\u00ED tak" . "Balc\u00E1rkov\u00E1, Jana" . . "9"^^ . "15110" . . . "Cytogenetika a molekul\u00E1rn\u00ED cytogenetika myelodysplastick\u00E9ho syndromu (MDS)"@cs . "Cytogenetika a molekul\u00E1rn\u00ED cytogenetika myelodysplastick\u00E9ho syndromu (MDS)" . . "CZ - \u010Cesk\u00E1 republika" . . "Urb\u00E1nkov\u00E1, Helena" . "54" . . . "[A3E67E7C9726]" . "Z(MSM6198959205)" . . "0042-773X" . "Prekopov\u00E1, Ivana" . . "Indr\u00E1kov\u00E1, Jarmila" . "Cytogenetika a molekul\u00E1rn\u00ED cytogenetika myelodysplastick\u00E9ho syndromu (MDS)"@cs . "Vondr\u00E1kov\u00E1, Jana" . . . . "RIV/61989592:15110/08:00007548" . "Holzerov\u00E1, Milena" . "Myelodysplastic syndrome (MDS) is clonal hematopoietic disease characterised by periherial cytopenias and bone marrow dysplasia. MDS is mainly disease of the eldery with median age of 60 years. 25 -30 % of patients with MDS transform to acute leukemia, most offen acute myeloid leukemia. Chromosomal aberrations are present in 50 % of primary MDS and up to 80 % of secondary MDS patients. Deletion on the long arm of chromosome 5 (5q-) is the most frequent chromosomal abnormality in MDS. A sole 5q deletion is associated with favorable prognosis whereas other cytogenetic changes including deletion/ monosomy of chromosome 7 and complex karyotype are associated with a poor outcome. The aim of our study was to detect chromosomal changes in patients with MDS using conventional cytogenetics, fluorescence and multicolor fluorescence in situ hybridization ( FISH and M-FISH)."@en . . . "Cytogenetics and molecular cytogenetics of myelodysplastic syndrom (MDS)"@en . "Myelodysplastick\u00FD syndrom je klon\u00E1ln\u00ED hematopoetick\u00E9 onemocn\u011Bn\u00ED charakterizovan\u00E9 cytopeni\u00ED a dysplasi\u00ED kostn\u00ED d\u0159en\u011B. Je to onemocn\u011Bn\u00ED vy\u0161\u0161\u00EDho v\u011Bku s medi\u00E1nem 60 let. Pro MDS je charakteristick\u00E1 \u0161patn\u00E1 odpov\u011B\u010F na chemoterapii s dlouhodob\u00FDmi cytopeniemi a n\u00EDzk\u00FDm po\u010Dtem remis\u00ED. U 25-30 % nemocn\u00FDch doch\u00E1z\u00ED po ur\u010Dit\u00E9 dob\u011B k postupn\u00E9mu v\u00FDvoji MDS do akutn\u00ED leukemie, nej\u010Dast\u011Bji do akutn\u00ED myeloidn\u00ED leukemie. U d\u011Bt\u00ED se MDS vyskytuje jen z\u0159\u00EDdka a pokud se vyskytne, je charakterizov\u00E1no rychlej\u0161\u00EDm pr\u016Fb\u011Bhem a zvratem do akutn\u00ED leukemie. Cytogenetick\u00E9 zm\u011Bny hraj\u00ED d\u016Fle\u017Eitou roli v patogenesi, diagnose a prognose a v posledn\u00ED dob\u011B se zvy\u0161uje i jejich v\u00FDznam p\u0159i v\u00FDb\u011Bru c\u00EDlen\u00E9 l\u00E9\u010Dby nemocn\u00FDch s MDS. Zm\u011Bny chromosom\u016F se objevuj\u00ED v erytroidn\u00EDch, myeloidn\u00EDch a megakaryocyt\u00E1rn\u00EDch prekursorov\u00FDch bu\u0148k\u00E1ch, co\u017E sv\u011Bd\u010D\u00ED o vzniku neoplasie v pluripotentn\u00ED kmenov\u00E9 bu\u0148ce. Chromosomov\u00E9 zm\u011Bny jsou p\u0159\u00EDtomn\u00E9 asi u 50 % nemocn\u00FDch s de novo MDS a a\u017E v 80 % nemocn\u00FDch se sekund\u00E1rn\u00ED MDS. Balancovan\u00E9 chromosomov\u00E9 zm\u011Bny, kter\u00E9 zahrnuj\u00ED tak"@cs . "RIV/61989592:15110/08:00007548!RIV09-MSM-15110___" . "361880" . "Cytogenetika a molekul\u00E1rn\u00ED cytogenetika myelodysplastick\u00E9ho syndromu (MDS)" .